US 7,589,180 B2
	Specific binding proteins and uses thereof
Lloyd J. Old, New York, N.Y. (US); Terrance Grant Johns, Melbourne (Australia); Con Panousis, Melbourne (Australia); Andrew Mark Scott, Kew (Australia); Christoph Renner, Homburg/Saar (Germany); Gerd Ritter, New York, N.Y. (US); Achim Jungbluth, New York, N.Y. (US); Elisabeth Stockert, New York, N.Y. (US); Peter Collins, Cambridge (United Kingdom); Webster K. Cavenee, Del Mar, Calif. (US); Huei-Jen Su Huang, Rancho Santa Fe, Calif. (US); Antony Wilks Burgess, Camberwell (Australia); and Edouard Collins Nice, St Kilda (Australia)
Assigned to Abbott Laboratories Inc., Abbott Park, Ill. (US)
Filed on May 13, 2002, as Appl. No. 10/145,598.
Claims priority of provisional application 60/290410, filed on May 11, 2001.
Claims priority of provisional application 60/326019, filed on Sep. 28, 2001.
Claims priority of provisional application 60/342258, filed on Dec. 21, 2001.
Prior Publication US 2009/0137782 A1, May 28, 2009
Int. Cl. C07K 16/28 (2006.01)

U.S. Cl. 530—387.3  [530/350; 530/387.1; 530/387.7; 530/388.8]

4 Claims

1. An antibody capable of binding EGFR on tumors containing amplifications of the EGFR gene, wherein cells of the tumor contain multiple copies of the EGFR gene, and on tumors that express the truncated version of the EGFR receptor de2-7, wherein said antibody does not bind to the de2-7 EGFR junctional peptide consisting of the amino acid sequence of SEQ ID NO: 13, wherein said antibody comprises a heavy chain and light chain and the heavy chain variable region sequence comprises polypeptide binding domain CDRs corresponding to amino acids 26-36, 50-65, and 97-105 of SEQ ID NO: 11 and the light chain variable region sequence comprises polypeptide binding domain CDRs corresponding to residues 24-34, 50-56, and 89-97 of SEQ ID NO: 12.